Anang A Shelat

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5394682/publications.pdf

Version: 2024-02-01

101 papers	5,249 citations	94433 37 h-index	98798 67 g-index
110 all docs	110 docs citations	110 times ranked	9707 citing authors

#	Article	IF	Citations
1	Chemical genetics of Plasmodium falciparum. Nature, 2010, 465, 311-315.	27.8	515
2	High-throughput assays for promiscuous inhibitors. , 2005, 1, 146-148.		300
3	Targeting Oxidative Stress in Embryonal Rhabdomyosarcoma. Cancer Cell, 2013, 24, 710-724.	16.8	252
4	Orthotopic patient-derived xenografts of paediatric solid tumours. Nature, 2017, 549, 96-100.	27.8	223
5	(+)-SJ733, a clinical candidate for malaria that acts through ATP4 to induce rapid host-mediated clearance of Plasmodium. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, E5455-62.	7.1	199
6	Nanomolar Affinity Small Molecule Correctors of Defective Î”F508-CFTR Chloride Channel Gating. Journal of Biological Chemistry, 2003, 278, 35079-35085.	3.4	192
7	Identification and Characterization of the First Small Molecule Inhibitor of MDMX. Journal of Biological Chemistry, 2010, 285, 10786-10796.	3.4	171
8	Scaffold composition and biological relevance of screening libraries. Nature Chemical Biology, 2007, 3, 442-446.	8.0	164
9	Targeting the DNA Repair Pathway in Ewing Sarcoma. Cell Reports, 2014, 9, 829-840.	6.4	141
10	Pemetrexed and Gemcitabine as Combination Therapy for the Treatment of Group3 Medulloblastoma. Cancer Cell, 2014, 25, 516-529.	16.8	128
11	Targeting Metabolic Reprogramming by Influenza Infection for Therapeutic Intervention. Cell Reports, 2017, 19, 1640-1653.	6.4	127
12	Catalysis, Specificity, and ACP Docking Site of Streptomyces coelicolor Malonyl-CoA:ACP Transacylase. Structure, 2003, 11, 147-154.	3.3	125
13	Global Phenotypic Screening for Antimalarials. Chemistry and Biology, 2012, 19, 116-129.	6.0	120
14	Searching for New Antimalarial Therapeutics amongst Known Drugs. Chemical Biology and Drug Design, 2006, 67, 409-416.	3.2	110
15	Identification of Therapeutic Targets in Rhabdomyosarcoma through Integrated Genomic, Epigenomic, and Proteomic Analyses. Cancer Cell, 2018, 34, 411-426.e19.	16.8	106
16	An Integrated InÂVitro and InÂVivo High-Throughput Screen Identifies Treatment Leads for Ependymoma. Cancer Cell, 2011, 20, 384-399.	16.8	105
17	Discovery of Trypanocidal Compounds by Whole Cell HTS of Trypanosoma brucei. Chemical Biology and Drug Design, 2006, 67, 355-363.	3.2	97
18	Discovery of Small Molecule Inhibitors of the Interaction of the Thyroid Hormone Receptor with Transcriptional Coregulators. Journal of Biological Chemistry, 2005, 280, 43048-43055.	3.4	96

#	Article	IF	Citations
19	Blocking an N-terminal acetylationâ€“dependent protein interaction inhibits an E3 ligase. Nature Chemical Biology, 2017, 13, 850-857.	8.0	80
20	Automated High-Throughput System to Fractionate Plant Natural Products for Drug Discovery. Journal of Natural Products, 2010, 73, 751-754.	3.0	79
21	Discovery of Small Molecules that Inhibit the Disordered Protein, p27Kip1. Scientific Reports, 2015, 5, 15686.	3.3	70
22	MYCN amplification and ATRX mutations are incompatible in neuroblastoma. Nature Communications, 2020, 11, 913.	12.8	66
23	BRAID: A Unifying Paradigm for the Analysis of Combined Drug Action. Scientific Reports, 2016, 6, 25523.	3.3	63
24	The Childhood Solid Tumor Network: A new resource for the developmental biology and oncology research communities. Developmental Biology, 2016, 411, 287-293.	2.0	63
25	Benzoflavone activators of the cystic fibrosis transmembrane conductance regulator: towards a pharmacophore model for the nucleotide-binding domain. Bioorganic and Medicinal Chemistry, 2003, 11, 4113-4120.	3.0	62
26	Nuclear ULK1 promotes cell death in response to oxidative stress through PARP1. Cell Death and Differentiation, 2016, 23, 216-230.	11.2	61
27	Identification of Small Molecule Activators of BMP Signaling. PLoS ONE, 2013, 8, e59045.	2.5	61
28	Development of Potent Purine-Derived Nitrile Inhibitors of the Trypanosomal Protease TbcatB. Journal of Medicinal Chemistry, 2008, 51, 545-552.	6.4	58
29	Systematic Screening Identifies Dual PI3K and mTOR Inhibition as a Conserved Therapeutic Vulnerability in Osteosarcoma. Clinical Cancer Research, 2015, 21, 3216-3229.	7.0	58
30	The second European interdisciplinary Ewing sarcoma research summit - A joint effort to deconstructing the multiple layers of a complex disease. Oncotarget, 2016, 7, 8613-8624.	1.8	55
31	The interdependence between screening methods and screening libraries. Current Opinion in Chemical Biology, 2007, 11, 244-251.	6.1	54
32	Discovery of trypanocidal thiosemicarbazone inhibitors of rhodesain and TbcatB. Bioorganic and Medicinal Chemistry Letters, 2008, 18, 2883-2885.	2.2	52
33	Phenylâ€Glutarimides: Alternative Cereblon Binders for the Design of PROTACs. Angewandte Chemie - International Edition, 2021, 60, 26663-26670.	13.8	45
34	Targeting Histone Demethylases in MYC-Driven Neuroblastomas with Ciclopirox. Cancer Research, 2017, 77, 4626-4638.	0.9	42
35	UPLC-MS-ELSD-PDA as a Powerful Dereplication Tool to Facilitate Compound Identification from Small-Molecule Natural Product Libraries. Journal of Natural Products, 2014, 77, 902-909.	3.0	41
36	Evaluation of artemisinins for the treatment of acute myeloid leukemia. Cancer Chemotherapy and Pharmacology, 2016, 77, 1231-1243.	2.3	41

#	Article	IF	Citations
37	A phase I trial of talazoparib and irinotecan with and without temozolomide in children and young adults with recurrent or refractory solid malignancies. European Journal of Cancer, 2020, 137, 204-213.	2.8	39
38	A Solid-Phase Approach to the Phallotoxins:Â Total Synthesis of [Ala7]-Phalloidin. Journal of Organic Chemistry, 2005, 70, 4578-4584.	3.2	38
39	Assay Optimization and Screening of RNA-Protein Interactions by AlphaScreen. Journal of Biomolecular Screening, 2007, 12, 946-955.	2.6	38
40	Metabolic Activation of CaMKII by Coenzyme A. Molecular Cell, 2013, 52, 325-339.	9.7	35
41	Ligand Binding Mode Prediction by Docking: Mdm2/Mdmx Inhibitors as a Case Study. Journal of Chemical Information and Modeling, 2014, 54, 648-659.	5.4	35
42	Discovery of Potent and Selective Inhibitors of Trypanosoma brucei Ornithine Decarboxylase. Journal of Biological Chemistry, 2010, 285, 16771-16781.	3.4	33
43	Development of a Cell-Based, High-Throughput Screening Assay for ATM Kinase Inhibitors. Journal of Biomolecular Screening, 2014, 19, 538-546.	2.6	32
44	Development and characterization of a human orthotopic neuroblastoma xenograft. Developmental Biology, 2015, 407, 344-355.	2.0	30
45	ABCG2 Transporter Expression Impacts Group 3 Medulloblastoma Response to Chemotherapy. Cancer Research, 2015, 75, 3879-3889.	0.9	30
46	ABCG2 requires a single aromatic amino acid to â€œclampâ€•substrates and inhibitors into the binding pocket. FASEB Journal, 2020, 34, 4890-4903.	0.5	30
47	A High-Throughput Screen Reveals New Small-Molecule Activators and Inhibitors of Pantothenate Kinases. Journal of Medicinal Chemistry, 2015, 58, 1563-1568.	6.4	28
48	Bromodomain-Selective BET Inhibitors Are Potent Antitumor Agents against MYC-Driven Pediatric Cancer. Cancer Research, 2020, 80, 3507-3518.	0.9	28
49	A High-Throughput Screening Method to Identify Small Molecule Inhibitors of Thyroid Hormone Receptor Coactivator Binding. Science Signaling, 2006, 2006, pl3-pl3.	3.6	27
50	Patient-derived models recapitulate heterogeneity of molecular signatures and drug response in pediatric high-grade glioma. Nature Communications, 2021, 12, 4089.	12.8	27
51	A high-throughput screen indicates gemcitabine and JAK inhibitors may be useful for treating pediatric AML. Nature Communications, 2019, 10, 2189.	12.8	26
52	Structure-Guided Development of Selective TbcatB Inhibitors. Journal of Medicinal Chemistry, 2009, 52, 6489-6493.	6.4	25
53	Modeling and targeting of erythroleukemia by hematopoietic genome editing. Blood, 2021, 137, 1628-1640.	1.4	25
54	Structurally Conserved Amino Acid W501 Is Required for RNA Helicase Activity but Is Not Essential for DNA Helicase Activity of Hepatitis C Virus NS3 Protein. Journal of Virology, 2003, 77, 571-582.	3.4	23

#	Article	IF	Citations
55	Discovery of novel, orally bioavailable, antileishmanial compounds using phenotypic screening. PLoS Neglected Tropical Diseases, 2017, 11, e0006157.	3.0	23
56	Exploiting a water network to achieve enthalpy-driven, bromodomain-selective BET inhibitors. Bioorganic and Medicinal Chemistry, 2018, 26, 25-36.	3.0	23
57	Combinatorial screening using orthotopic patient derived xenograft-expanded early phase cultures of osteosarcoma identify novel therapeutic drug combinations. Cancer Letters, 2019, 442, 262-270.	7.2	23
58	Ventromorphins: A New Class of Small Molecule Activators of the Canonical BMP Signaling Pathway. ACS Chemical Biology, 2017, 12, 2436-2447.	3.4	20
59	MAIP: a web service for predicting bloodâ€stage malaria inhibitors. Journal of Cheminformatics, 2021, 13, 13.	6.1	20
60	The role of ZA channel water-mediated interactions in the design of bromodomain-selective BET inhibitors. Journal of Molecular Graphics and Modelling, 2018, 81, 197-210.	2.4	18
61	Novel vitexin-inspired scaffold against leukemia. European Journal of Medicinal Chemistry, 2018, 146, 501-510.	5.5	17
62	Robust Classification of Small-Molecule Mechanism of Action Using a Minimalist High-Content Microscopy Screen and Multidimensional Phenotypic Trajectory Analysis. PLoS ONE, 2016, 11, e0149439.	2.5	17
63	Small Molecule Sequestration of the Intrinsically Disordered Protein, p27Kip1, Within Soluble Oligomers. Journal of Molecular Biology, 2021, 433, 167120.	4.2	16
64	Optimization of a Non-Radioactive High-Throughput Assay for Decarboxylase Enzymes. Assay and Drug Development Technologies, 2010, 8, 175-185.	1.2	15
65	Shared Consensus Machine Learning Models for Predicting Blood Stage Malaria Inhibition. Journal of Chemical Information and Modeling, 2017, 57, 445-453.	5.4	15
66	Alteration of RNA Splicing by Small-Molecule Inhibitors of the Interaction between NHP2L1 and U4. SLAS Discovery, 2018, 23, 164-173.	2.7	14
67	Design of a selective chemical probe for class I PDZ domains. Bioorganic and Medicinal Chemistry Letters, 2007, 17, 546-548.	2.2	13
68	A High-Content Screen Identifies Inhibitors of Nuclear Export of Forkhead Transcription Factors. Journal of Biomolecular Screening, 2011, 16, 394-404.	2.6	12
69	Establishing a Preclinical Multidisciplinary Board for Brain Tumors. Clinical Cancer Research, 2018, 24, 1654-1666.	7.0	12
70	Preclinical studies of 5-fluoro-2â€²-deoxycytidine and tetrahydrouridine in pediatric brain tumors. Journal of Neuro-Oncology, 2016, 126, 225-234.	2.9	11
71	A Screening-Based Approach to Circumvent Tumor Microenvironment-Driven Intrinsic Resistance to BCR-ABL+ Inhibitors in Ph+ Acute Lymphoblastic Leukemia. Journal of Biomolecular Screening, 2014, 19, 158-167.	2.6	10
72	A critical evaluation of methods to interpret drug combinations. Scientific Reports, 2020, 10, 5144.	3.3	10

#	Article	IF	Citations
73	Synthesis and evaluation of colletoic acid core derivatives. European Journal of Medicinal Chemistry, 2016, 110, 126-132.	5.5	8
74	Targeted Inhibition of the MLL Transcriptional Complex By Proteosome Inhibitors Elicits a High Response Rate in Relapsed/Refractory MLL Rearranged Leukemia. Blood, 2014, 124, 972-972.	1.4	8
75	Identification of substituted 5-membered heterocyclic compounds as potential anti-leukemic agents. European Journal of Medicinal Chemistry, 2019, 164, 391-398.	5.5	7
76	17-DMAG dually inhibits Hsp90 and histone lysine demethylases in alveolar rhabdomyosarcoma. IScience, 2021, 24, 101996.	4.1	7
77	Virtual-screening workflow tutorials and prospective results from the Teach-Discover-Treat competition 2014 against malaria. F1000Research, 2017, 6, 1136.	1.6	7
78	Virtual-screening workflow tutorials and prospective results from the Teach-Discover-Treat competition 2014 against malaria. F1000Research, 2018, 6, 1136.	1.6	6
79	Evaluating and evolving a screening library in academia: the St Jude approach. Drug Discovery Today, 2021, 26, 1060-1069.	6.4	6
80	SLFN11 is Widely Expressed in Pediatric Sarcoma and Induces Variable Sensitization to Replicative Stress Caused By DNA-Damaging Agents. Molecular Cancer Therapeutics, 2021, 20, 2151-2165.	4.1	6
81	An Automated Approach to Efficiently Reformat a Large Collection of Compounds. Current Chemical Genomics, 2011, 5, 42-47.	2.0	5
82	A road less traveled by: Exploring a decade of Ellman chemistry. Bioorganic and Medicinal Chemistry, 2009, 17, 1088-1093.	3.0	4
83	Diversity-oriented natural product platform identifies plant constituents targeting Plasmodium falciparum. Malaria Journal, 2016, 15, 270.	2.3	4
84	Using response surface models to analyze drug combinations. Drug Discovery Today, 2021, 26, 2014-2024.	6.4	4
85	PARP inhibitor combination therapy in desmoplastic small round cell tumors.. Journal of Clinical Oncology, 2017, 35, e23212-e23212.	1.6	4
86	Modelâ€based evaluation of imageâ€guided fractionated wholeâ€brain radiation therapy in pediatric diffuse intrinsic pontine glioma xenografts. CPT: Pharmacometrics and Systems Pharmacology, 2021, 10, 599-610.	2.5	3
87	Metabolic Activation of CaMKII by Coenzyme A. Molecular Cell, 2013, 52, 468.	9.7	1
88	Targeting the cell cycle for cancer therapy in rhabdomyosarcoma.. Journal of Clinical Oncology, 2017, 35, 10535-10535.	1.6	1
89	Phenylâ€Glutarimides: Alternative Cereblon Binders for the Design of PROTACs. Angewandte Chemie, 0, , .	2.0	1
90	A biomarker-guided approach to combining PARP inhibitors with radiotherapy in pediatric solid tumors.. Journal of Clinical Oncology, 2017, 35, 10556-10556.	1.6	1

#	Article	IF	Citations
91	Data vignettes for the application of response surface models in drug combination analysis. Data in Brief, 2021, 38, 107400.	1.0	0
92	Incorporating PARP inhibitors in translational studies for Ewingâ€™s sarcoma.. Journal of Clinical Oncology, 2014, 32, e21025-e21025.	1.6	0
93	Preclinical evaluation of PARP inhibitors in combination with DNA-damaging agents in a Ewing sarcoma orthotopic xenograft model.. Journal of Clinical Oncology, 2014, 32, 10073-10073.	1.6	0
94	Molecular analysis of solid tumors (MAST): A protocol for comprehensive preclinical evaluation of pediatric solid tumors.. Journal of Clinical Oncology, 2014, 32, 10036-10036.	1.6	0
95	Integrated High-Throughput Screen to Identify Novel Treatment Leads for Pediatric Acute Myeloid Leukemia. SSRN Electronic Journal, 0, , .	0.4	0
96	Is Inhibitor Binding the Sole Requirement in Determining Inhibition of ABCG2 Mediated Transport?. FASEB Journal, 2018, 32, 693.9.	0.5	0
97	Multiplex CRISPR/Cas9-Based Genome Editing of Mouse Hematopoietic Stem Cells Recapitulates Acute Erythroid Leukemia and Identifies Therapeutic Targets. Blood, 2018, 132, 5-5.	1.4	0
98	Determining the Molecular Characteristics of How Ligands Interact with an ABC Transporter. FASEB Journal, 2019, 33, 507.4.	0.5	0
99	Loss of PTEN in Pediatric AML Confers Sensitivity to PARP Inhibition. Blood, 2021, 138, 3446-3446.	1.4	0
100	An Evolutionarily Conserved Residue in ABCG2 Regulates the Transport Cycle and Inhibitor Activity. FASEB Journal, 2022, 36, .	0.5	0
101	INSP-09. Using genetically engineered mouse models and patient-derived orthotopic xenografts to develop new therapies for pediatric brain tumors.. Neuro-Oncology, 2022, 24, i188-i188.	1.2	0